Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariana Segovia

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Sensors (Basel, Switzerland)|July 27, 2022
Design, Modeling and Implementation of Digital TwinsMariana Segovia, Joaquin Garcia-Alfaro
Frontiers in Immunology|March 19, 2019
Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer PhysiopathologyMariana Segovia-Mendoza, Jorge Morales-Montor
Environmental Toxicology and Pharmacology|March 1, 2024
Cardiovascular disrupting effects of bisphenols, phthalates, and parabens related to endothelial dysfunction: Review of toxicological and pharmacological mechanismsCristina Lemini, Patricia Silveyra, Mariana Segovia-Mendoza
Frontiers in Oncology|December 26, 2022
Editorial: Exploring the breast tumor microenvironment: Association to metastasis, novel risk factors and novel treatments and immunotherapiesKaren Elizabeth Nava-Castro, Mariana Segovia-Mendoza, Jorge Morales-Montor
International Journal of Molecular Sciences|December 10, 2021
Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An UpdateMariana Segovia-Mendoza, Janice García-Quiroz, Lorenza Díaz, et al.
Journal of Immunology Research|January 28, 2021
Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition ActivationMariana Segovia-Mendoza, Susana Romero-Garcia, Cristina Lemini, et al.
Biological & Pharmaceutical Bulletin|January 4, 2021
Potential Estrogenic Properties of 17β-Hydroxy-ethylimine Estradiol Derivative Targeted to Menopause StageGuadalupe Luisa Jimenez-Sánchez, Mariana Segovia-Mendoza, Alejandra Figueroa, et al.
American Journal of Cancer Research|November 27, 2015
Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceMariana Segovia-Mendoza, María E González-González, David Barrera, et al.
International Journal of Environmental Research and Public Health|October 14, 2022
The Interplay of GPER1 with 17β-Aminoestrogens in the Regulation of the Proliferation of Cervical and Breast Cancer Cells: A Pharmacological ApproachMariana Segovia-Mendoza, Elahe Mirzaei, Heriberto Prado-Garcia, et al.
BMC Cancer|January 28, 2015
Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo studyMariana Segovia-Mendoza, Rafael Jurado, Roser Mir, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Sensors (Basel, Switzerland)|July 27, 2022
Design, Modeling and Implementation of Digital TwinsMariana Segovia, Joaquin Garcia-Alfaro
Frontiers in Immunology|March 19, 2019
Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer PhysiopathologyMariana Segovia-Mendoza, Jorge Morales-Montor
Environmental Toxicology and Pharmacology|March 1, 2024
Cardiovascular disrupting effects of bisphenols, phthalates, and parabens related to endothelial dysfunction: Review of toxicological and pharmacological mechanismsCristina Lemini, Patricia Silveyra, Mariana Segovia-Mendoza
Frontiers in Oncology|December 26, 2022
Editorial: Exploring the breast tumor microenvironment: Association to metastasis, novel risk factors and novel treatments and immunotherapiesKaren Elizabeth Nava-Castro, Mariana Segovia-Mendoza, Jorge Morales-Montor
International Journal of Molecular Sciences|December 10, 2021
Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An UpdateMariana Segovia-Mendoza, Janice García-Quiroz, Lorenza Díaz, et al.
Journal of Immunology Research|January 28, 2021
Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition ActivationMariana Segovia-Mendoza, Susana Romero-Garcia, Cristina Lemini, et al.
Biological & Pharmaceutical Bulletin|January 4, 2021
Potential Estrogenic Properties of 17β-Hydroxy-ethylimine Estradiol Derivative Targeted to Menopause StageGuadalupe Luisa Jimenez-Sánchez, Mariana Segovia-Mendoza, Alejandra Figueroa, et al.
American Journal of Cancer Research|November 27, 2015
Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceMariana Segovia-Mendoza, María E González-González, David Barrera, et al.
International Journal of Environmental Research and Public Health|October 14, 2022
The Interplay of GPER1 with 17β-Aminoestrogens in the Regulation of the Proliferation of Cervical and Breast Cancer Cells: A Pharmacological ApproachMariana Segovia-Mendoza, Elahe Mirzaei, Heriberto Prado-Garcia, et al.
BMC Cancer|January 28, 2015
Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo studyMariana Segovia-Mendoza, Rafael Jurado, Roser Mir, et al.
Pageof 4